{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:39:02Z","timestamp":1772138342224,"version":"3.50.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Cancer Research UK Population Research Postdoctoral Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study Question<\/jats:title>\n                    <jats:p>Is hormone replacement therapy (HRT) associated with an increased risk of melanoma skin cancer or prognostic outcomes amongst post-menopausal women?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>Whilst we found evidence of an association with melanoma risk, the lack of dose-response and associations observed with recent use, localised disease and intravaginal oestrogens suggests this is a non-causal association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>Evidence on HRT and melanoma risk remains inconclusive, with studies providing conflicting results. Furthermore, evidence on melanoma survival is sparse, with only one previous study reporting protective associations with HRT use, likely attributable to immortal time bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>We conducted a nation-wide population-based case-control study and a retrospective cohort study utilising the Danish healthcare registries. Case-control analyses included 8279 women aged 45\u201385 with a first-ever diagnosis of malignant melanoma between 2000 and 2015, matched by age and calendar time to 165\u2009580 population controls. A cohort of 6575 patients with a diagnosis of primary malignant melanoma between 2000 and 2013 and followed through 2015 was examined to determine if HRT use had an impact on melanoma survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Based on prescriptions dispensed since 1995, ever-use of HRT was defined as having filled at least one prescription for HRT prior to the index date. In total, 2629 cases (31.8%) and 47\u2009026 controls (28.4%) used HRT. Conditional logistic regression was used to calculate odds ratios (ORs) for melanoma risk according to HRT use, compared with non-use, adjusting for potential confounders. For cohort analyses, Cox proportional hazards models was used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for second melanoma incidence and all-cause mortality associated with HRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>High use of HRT was associated with an OR of 1.21 (95% CI 1.13\u20131.29) for melanoma risk, with no evidence of a dose-response pattern. Results were most pronounced amongst recent high users (OR, 1.28; 95% CI 1.17\u20131.41), for localised disease (OR, 1.25; 95% CI 1.15\u20131.36) and for intravaginal oestrogen therapy (OR, 1.38; 95% CI 1.13\u20131.68). Compared with non-use, there was no evidence of an association for secondary melanoma for post-diagnostic new-use (fully adjusted HR, 1.56; 95% CI 0.64\u20133.80) or continuous HRT use (fully adjusted HR, 1.26; 95% CI 0.89\u20131.78). Similar associations were observed for all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>Despite the large sample size and the use of robust population-based registries with almost complete coverage, we lacked information on some important confounders including sun exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>Whilst we cannot rule out an association between HRT use and melanoma risk, the associations observed are also compatible with increased healthcare utilisation and thus increased melanoma detection amongst HRT users. No association between HRT use and melanoma survival outcomes was observed. This should provide some reassurance to patients and clinicians, particularly concerning the use of HRT in patients with a history of melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>B.M.H. is funded by a Cancer Research UK Population Research Postdoctoral Fellowship. The funding source had no influence on the design or conduct of this study. A.P. reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Servier, Novo Nordisk and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this article. The other authors have no competing interests to declare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>N\/A.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/dez222","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:37:55Z","timestamp":1570030675000},"page":"2418-2429","source":"Crossref","is-referenced-by-count":18,"title":["Hormone replacement therapy and the risk of melanoma in post-menopausal women"],"prefix":"10.1093","volume":"34","author":[{"given":"B M","family":"Hicks","sequence":"first","affiliation":[{"name":"Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen\u2019s University Belfast, Belfast, Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K B","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S A","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Clinical Pharmacology, Odense University Hospital, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L R","family":"H\u00f6lmich","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Herlev and Gentofte Hospital, Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"2019123012291331000_ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2014.10.010","article-title":"Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish population-based register study 1989\u20132011","volume":"39","author":"Bay","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"2019123012291331000_ref2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.maturitas.2003.09.031","article-title":"Hormone replacement therapy in cancer survivors","volume":"48","author":"Biglia","year":"2004","journal-title":"Maturitas"},{"key":"2019123012291331000_ref3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1403494810393563","article-title":"The Danish pathology register","volume":"39","author":"Bjerregaard","year":"2011","journal-title":"Scand J Public Health"},{"key":"2019123012291331000_ref4","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/ijc.30878","article-title":"Menopausal hormone therapy and risk of melanoma: do estrogens and progestins have a different role?","volume":"141","author":"Botteri","year":"2017","journal-title":"Int J Cancer"},{"key":"2019123012291331000_ref5","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/ijc.32150","article-title":"Postmenopausal hormone use and cutaneous melanoma risk: a French prospective cohort study","volume":"145","author":"Cervenka","year":"2019","journal-title":"Int J Cancer"},{"key":"2019123012291331000_ref6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2019123012291331000_ref7","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/aje\/kwp304","article-title":"Mammographic screening and risk factors for breast cancer","volume":"170","author":"Cook","year":"2009","journal-title":"Am J Epidemiol"},{"key":"2019123012291331000_ref8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1186\/s12885-016-2836-6","article-title":"Risk factors for cancer development in type 2 diabetes: a retrospective case-control study","volume":"16","author":"D\u0105browski","year":"2016","journal-title":"BMC Cancer"},{"key":"2019123012291331000_ref9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-1440-3-10","article-title":"Systematic review of melanoma incidence and prognosis in solid organ transplant recipients","volume":"3","author":"Dahlke","year":"2014","journal-title":"Transplant Res"},{"key":"2019123012291331000_ref10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41416-019-0411-z","article-title":"ARTICLE epidemiology reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States","volume":"120","author":"Donley","year":"2019","journal-title":"Br J Cancer"},{"key":"2019123012291331000_ref11","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/cam4.1152","article-title":"Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011","volume":"6","author":"Enninga","year":"2017","journal-title":"Cancer Med"},{"key":"2019123012291331000_ref12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/tri.13011","article-title":"Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study","volume":"30","author":"Fattouh","year":"2017","journal-title":"Transpl Int"},{"key":"2019123012291331000_ref13","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.ejca.2011.04.023","article-title":"Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis","volume":"47","author":"Gandini","year":"2011","journal-title":"Eur J Cancer"},{"key":"2019123012291331000_ref14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma: II Sun exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"2019123012291331000_ref15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2005.03.034","article-title":"Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"2019123012291331000_ref16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/era.11.42","volume":"11","author":"Giorgi","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"2019123012291331000_ref17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish cancer registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand J Public Health"},{"key":"2019123012291331000_ref18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2340\/00015555-2148","article-title":"Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies","volume":"95","author":"Green","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2019123012291331000_ref19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ndt\/gfx190","article-title":"Long-term consequences of renal insufficiency in children: lessons learned from the Dutch LERIC study","volume":"33","author":"Groothoff","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2019123012291331000_ref20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaad.2014.09.024","article-title":"Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women\u2019s health initiative","volume":"72","author":"Henderson","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2019123012291331000_ref21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6604796","article-title":"Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin\u2019s lymphoma: a population-based case-control study","volume":"100","author":"Jensen","year":"2009","journal-title":"Br J Cancer"},{"key":"2019123012291331000_ref22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0378-5122(95)00964-7","article-title":"Sociological and behavioural characteristics of perimenopausal women with an express attitude to hormone substitution therapy","volume":"23","author":"Jensen","year":"1996","journal-title":"Maturitas"},{"key":"2019123012291331000_ref23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1403494810394715","article-title":"Danish education registers","volume":"39","author":"Jensen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2019123012291331000_ref24","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1158\/1055-9965.EPI-10-0652","article-title":"Photosensitizing medication use and risk of skin cancer","volume":"19","author":"Kaae","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2019123012291331000_ref25","volume-title":"Modern Epidemiology","author":"Rothman","year":"2008"},{"key":"2019123012291331000_ref26","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/aje\/kwq503","article-title":"Cutaneous melanoma and endogenous hormonal factors: a large French prospective study","volume":"173","author":"Kvaskoff","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2019123012291331000_ref27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/gme.0b013e31817b6132","article-title":"Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"2019123012291331000_ref28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/jech.57.4.294","article-title":"Health status of users of hormone replacement therapy by hysterectomy status in Western Australia","volume":"57","author":"Lambert","year":"2003","journal-title":"J Epidemiol Community Health"},{"key":"2019123012291331000_ref29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00042192-200007040-00010","article-title":"Women\u2019s health in Lund area (WHILA) study. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women\u2019s health in Lund area (WHILA) study","volume":"7","author":"Li","year":"2000","journal-title":"Menopause"},{"key":"2019123012291331000_ref30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jaad.2017.11.050","article-title":"Statin use and risk of skin cancer","volume":"78","author":"Lin","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2019123012291331000_ref31","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/sj.bjc.6601595","article-title":"Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma","volume":"90","author":"Mackie","year":"2004","journal-title":"Br J Cancer"},{"key":"2019123012291331000_ref32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/13697139809080680","article-title":"Hormone replacement therapy: prevalence, compliance and the \u201chealthy women\u201d notion","volume":"1","author":"MacLennan","year":"1998","journal-title":"Climacteric"},{"key":"2019123012291331000_ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2016.00140","article-title":"Estrogen receptor \u03b2 in melanoma: from molecular insights to potential clinical utility","volume":"7","author":"Marzagalli","year":"2016","journal-title":"Front Endocrinol"},{"key":"2019123012291331000_ref34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaad.2015.08.034","article-title":"Can oral nonsteroidal antiinflammatory drugs play a role in the prevention of basal cell carcinoma? A systematic review and metaanalysis","volume":"74","author":"Muranushi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2019123012291331000_ref35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/jid.2014.531","article-title":"Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis","volume":"135","author":"Muranushi","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2019123012291331000_ref36","author":"NORDCAN, Cancer Statistics for the Nordic Countries","year":"2019","journal-title":"Cancer Stat Fact Sheets: Nordic Countries- Melanoma of Skin"},{"key":"2019123012291331000_ref38","doi-asserted-by":"crossref","first-page":"e95096","DOI":"10.1371\/journal.pone.0095096","article-title":"Risk of melanoma in people with HIV\/AIDS in the pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies","volume":"9","author":"Olsen","year":"2014","journal-title":"PLoS One"},{"key":"2019123012291331000_ref39","doi-asserted-by":"crossref","first-page":"dyw213","DOI":"10.1093\/ije\/dyw213","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2019123012291331000_ref40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJM197801262980406","article-title":"Absorption of Estrogens from vaginal creams","volume":"298","author":"Rigg","year":"1978","journal-title":"N Engl J Med"},{"key":"2019123012291331000_ref41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"2019123012291331000_ref42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish civil registration system as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"2019123012291331000_ref43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2019123012291331000_ref44","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12921","article-title":"Use of antihypertensive drugs and risk of skin cancer","volume":"29","author":"Schmidt","year":"2015","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"2019123012291331000_ref45","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ejca.2012.08.028","article-title":"Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies","volume":"49","author":"Sergentanis","year":"2013","journal-title":"Eur J Cancer"},{"key":"2019123012291331000_ref46","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15760","article-title":"Sex matters: men with melanoma have a worse prognosis than women","author":"Sharouni","year":"2019","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"2019123012291331000_ref47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0020-7292(03)00200-5","article-title":"Local estrogen treatment in patients with urogenital symptoms","volume":"82","author":"Simuni\u0107","year":"2003","journal-title":"Int J Gynaecol Obstet"},{"key":"2019123012291331000_ref48","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ije\/dys146","article-title":"Smoking and risk of skin cancer: a prospective analysis and a meta-analysis","volume":"41","author":"Song","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2019123012291331000_ref49","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM198405033101805","article-title":"Cutaneous squamous-cell carcinoma in patients treated with PUVA","volume":"310","author":"Stern","year":"1984","journal-title":"N Engl J Med"},{"key":"2019123012291331000_ref50","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/jnci\/djr333","article-title":"Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women\u2019s health initiative randomized trials","volume":"103","author":"Tang","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2019123012291331000_ref51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1403494811399956","article-title":"Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving","volume":"39","author":"Thygesen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2019123012291331000_ref52","doi-asserted-by":"crossref","first-page":"e4070","DOI":"10.1097\/MD.0000000000004070","article-title":"Risk of skin cancer in patients with diabetes mellitus","volume":"95","author":"Tseng","year":"2016","journal-title":"Medicine"},{"key":"2019123012291331000_ref53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish national prescription registry","volume":"39","author":"Wallach Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"2019123012291331000_ref54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.contraception.2009.03.005","article-title":"Inhibitory effects of progestogens on the estrogen stimulation of melanocytes in vitro","volume":"80","author":"Wiedemann","year":"2009","journal-title":"Contraception"},{"key":"2019123012291331000_ref55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J Oncol Pract"},{"key":"2019123012291331000_ref56","article-title":"WHO collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2018","author":"World Health Organisation"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/34\/12\/2418\/31642503\/dez222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/34\/12\/2418\/31642503\/dez222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T12:30:20Z","timestamp":1577709020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/34\/12\/2418\/5658564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":55,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,5]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/dez222","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737038140.793571268","asserted-by":"object"}]},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12,1]]}}}